Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest NovelMed Therapeutics Inc. Stories

2013-10-07 12:25:43

BIO Investor Forum to be held October 8-9 in San Francisco, California CLEVELAND, Oct. 7, 2013 /PRNewswire-USNewswire/ -- NovelMed Therapeutics, Inc. will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 8-9 at the Palace Hotel in San Francisco, California. (Logo:...

2013-09-25 08:29:22

Humanized Antibody for Orphan & Non-Orphan Ocular Disorders CLEVELAND, Sept. 25, 2013 /PRNewswire-USNewswire/ -- Today NovelMed Therapeutics announced preclinical study results for its lead compound in two models of AMD, a major cause of blindness affecting more than 2 million people in the United States. (Logo: http://photos.prnewswire.com/prnh/20130909/DC73243LOGO) Two independent preclinical investigations demonstrated that NovelMed's lead compound, an alternative pathway...

2013-09-09 12:27:47

Novel Humanized Antibody Approach May Lead to Safer, More Cost Effective Treatment CLEVELAND, Sept. 9, 2013 /PRNewswire-USNewswire/ -- NovelMed Therapeutics (www.novelmed.com) announced the receipt of a combined $1.43 million SBIR Grant from the NIH. The first installment of the award (for $542,572) will be used to evaluate NovelMed's lead candidate's therapeutic superiority for treating Paroxysmal Nocturnal Hemoglobinuria (PNH). Subsequent funding, to be released on demonstration...